Lede:
Dire wolves and woolly mammoths may soon walk the Earth again, and according to Colossal Biosciences CEO Ben Lamm, their return could hold surprising benefits for humans. The company believes de-extinction efforts may extend human life by contributing to advances in conservation, healthcare, and developmental biology.
Bringing lost species back from extinction has long fascinated scientists and storytellers alike. While once considered the stuff of science fiction, recent breakthroughs in genetic sequencing and cloning technology have made the idea seem more tangible. Proponents argue that reconstructing ancient genomes could offer insights into modern medicine and ecological restoration.
KEY FACTS:
- Colossal Biosciences CEO Ben Lamm discussed de-extinction’s potential.
- Dire wolves and woolly mammoths are among the species targeted for revival.
- The process may support conservation, healthcare, and developmental biology.
- These advances might contribute to extending human life.
THE STORY:
What Is De-extinction?
De-extinction refers to the process of reviving species that have gone extinct. This typically involves extracting DNA from preserved specimens or related living species, editing it using CRISPR or similar tools, and implanting it into surrogate animals. In the case of dire wolves and woolly mammoths, researchers often rely on close living relatives—such as gray wolves and Asian elephants—to help reconstruct key traits.
How Could This Help Humans?
Ben Lamm suggests that de-extinction could yield unexpected benefits beyond restoring biodiversity. By studying how extinct creatures adapted to past climates or diseases, scientists may uncover genetic mechanisms useful in treating modern conditions. Additionally, refining techniques used in cloning and tissue engineering may translate directly into regenerative medicine applications.
Who Is Leading These Efforts?
Colossal Biosciences is one firm actively pursuing de-extinction projects. Though progress remains early, the company aims to apply findings toward both ecological goals and biomedical research. However, independent verification of claimed outcomes remains limited as most results have not yet been published in peer-reviewed journals.
What We Know — and What We Don’t:
Verified by the source:
- CEO Ben Lamm stated de-extinction contributes to conservation, healthcare, and developmental biology.
- He named dire wolves and woolly mammoths as targets for revival.
- Potential links between de-extinction and human longevity were mentioned.
Still unconfirmed:
- No clinical trials or peer-reviewed studies proving health extensions.
- Timeline for successful revivals has not been specified.
- Independent scientific validation of de-extinction claims is missing.
Why It Matters:
While de-extinction captures public imagination, its real value may lie in advancing biotechnology that helps humans adapt to an evolving world. Understanding ancient life forms can reveal new pathways in medicine and ecology, potentially reshaping industries across [economy-markets] and [tech-ai].
What To Watch:
Official announcements or trial updates from Colossal Biosciences would clarify whether de-extinction moves closer to reality or remains speculative.